QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=A043B438A3B5591667B8740B38982408;jsessionid=A619E267BCB13362939393AACC1814CF;jsessionid=637D4A507FB092A4C6EF2E7FEC025755;jsessionid=1C35E3400CB1E607FE76ED4EEBE2F3FC;jsessionid=2CDF77A328D1AB3ADAA30F89AEA30DCB;jsessionid=703F79554320B465CE7011BCD7A6F41B;jsessionid=9AE53CA0EE907C6CBD16F1E99266A933 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=A043B438A3B5591667B8740B38982408;jsessionid=A619E267BCB13362939393AACC1814CF;jsessionid=637D4A507FB092A4C6EF2E7FEC025755;jsessionid=1C35E3400CB1E607FE76ED4EEBE2F3FC;jsessionid=2CDF77A328D1AB3ADAA30F89AEA30DCB;jsessionid=703F79554320B465CE7011BCD7A6F41B;jsessionid=9AE53CA0EE907C6CBD16F1E99266A933